Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 4, 2019updated 07 Aug 2019 2:55pm

Pfizer starts Phase IIb/III trial of PF-06651600 for alopecia areata

Pfizer has commenced a Phase IIb/III clinical trial to evaluate the safety and effectiveness of PF-06651600 for the treatment of patients with moderate to severe alopecia areata.

Pfizer has commenced a Phase IIb/III clinical trial to evaluate the safety and effectiveness of PF-06651600 for the treatment of patients with moderate to severe alopecia areata.

Alopecia areata is a chronic autoimmune skin disease that results in hair loss on the scalp, face, or body. There is no approved therapy available for the disease.

The randomised, double-blind, dose-ranging trial aims to include adult and adolescent alopecia sufferers with 50% or greater scalp hair loss.

Approximately 660 patients are expected to be enrolled in the study.

“Pfizer has several selective kinase programmes in the clinic with studies spanning across rheumatology, gastrointestinal disorders, and medical dermatology.”

Primary endpoint of the placebo-controlled trial is the percentage of patients achieving an absolute severity of alopecia tool (SALT) score <=10 at week 24.

The trial’s secondary endpoints include percentage of patients achieving a SALT score of <=10 and change from baseline in alopecia areata patient priority outcomes (AAPPO) scale scores.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Pfizer Global product development inflammation and immunology chief development officer Michael Corbo said: “Including our JAK3 programme, Pfizer has several selective kinase programmes in the clinic with studies spanning across rheumatology, gastrointestinal disorders, and medical dermatology, where we aspire to deliver potentially transformative medicines to those living with chronic autoimmune and inflammatory conditions.”

Pfizer’s PF-06651600 is an oral JAK3 inhibitor that received breakthrough therapy designation from the US Food and Drug Administration (FDA) to treat alopecia in September last year.

PF-06651600 is also currently being studied for the treatment of rheumatoid arthritis, Crohn’s disease and ulcerative colitis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU